Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
Kidney Diseases · 2023 · 9 (1) · 1-11
DOI: 10.1159/000527835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney Diseases, online erschienen am 31.10.2022. Verfasst von Jing Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Anemia is a common complication of chronic kidney disease. The hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the treatment of renal anemia. Summary: Clinical trials have consistently shown that HIF-PHIs can effectively increase hemoglobin in both the dialysis population and the nondialysis population. The effects of HIF-PHIs in treating renal anemia include promoting endogenous erythropoietin production and facilitating iron mobilization. Several studies suggest that the erythropoiesis effect of roxadustat is less affected by inflammation. Careful monitoring of thromboembolic events and tumor before and during HIF-PHI treatment is necessary. Key Messages: HIF-PHIs are effective in correcting renal anemia. The long-term safety of HIF-PHIs needs to be further studied.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Medicine, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Department of Molecular Physiology & Biophysics and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Section of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Zitieren
APA
Li, J., Haase, V. H., & Hao, C. M. (2023). Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia. Kidney Diseases, 9(1), 1-11. https://doi.org/10.1159/000527835
Vancouver
Li J, Haase VH, Hao CM. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia. Kidney Diseases. 2023;9(1):1-11. doi:10.1159/000527835
BibTeX
@article{Li2023,
author = {Li, Jing and Haase, Volker H and Hao, Chuan-Ming},
title = {Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia},
journal = {Kidney Diseases},
year = {2023},
volume = {9},
number = {1},
pages = {1--11},
doi = {10.1159/000527835}
}
EUVIMED